COURSE DESCRIPTION

The training course focuses on identifying the early indicators of alpha-mannosidosis (AM), a highly uncommon genetic condition caused by a deficiency in the alpha-mannosidase enzyme. Due to the wide range of symptoms, varying severity, and individual progression rates, diagnosing alpha-mannosidosis is often complex and subject to delays. Prompt diagnosis is crucial for providing affected individuals and their families with early access to necessary support and specialized multidisciplinary team (MDT) care. Our expert presenters delve into the varied symptoms associated with alpha-mannosidosis, address the difficulties in achieving a timely diagnosis, and share effective strategies for sustained management and multidisciplinary treatment. The course includes case studies, actionable guidance, and readings for a comprehensive learning experience."

TARGET AUDIENCE

This educational activity is designed for an international audience of Pediatricians, General Practitioners and other physicians and healthcare professionals interested in Rare Diseases and Alpha-mannosidosis.

COURSE CURRICULUM

  • 1

    MODULE 1: Essential Insights into Alpha-Mannosidosis and Its Early Clinical Signs

    • Training Video: Dr. Martin Magner's Comprehensive Overview of Alpha-Mannosidosis and Its Early Clinical Indicators

    • Further Readings (Optional)

    • Test of Module 1

  • 2

    MODULE 2: Practical Approaches to Diagnosing Alpha-Mannosidosis

    • Training Video: Dr. Nathalie Guffon's Guide on Diagnosing Alpha-Mannosidosis in Clinical Practice

    • Further Readings (Optional)

    • Test of Module 2
  • 3

    MODULE 3: Transitioning from Diagnosis to Early Treatment in Alpha-Mannosidosis

    • Training Video: Dr. Florian Lagler's Insights on Moving from Diagnosis to Early Stage Treatment in Alpha-Mannosidosis

    • Further Readings (Optional)

    • Test of Module 3
  • 4

    MODULE 4: What Every Paediatrician Needs to Know about the AM Patient’s Journey

    • Training Video: Dr. Christina Lampe Discusses Essential Knowledge for Pediatricians on the Alpha-Mannosidosis Patient's Experience

    • Test of Module 4
  • 5

    EVALUATION

    • Evaluation Survey

INSTRUCTORS

COURSE EXAM AND CERTIFICATE

Complete the test in each module to get your certificate

At the end of each module, you will be able to assess your level of understanding with a short test. This will help you to determine your understanding of the course material and identify sections you may wish to revisit. With a minimum passing grade of 75%, you will receive the certificate once you complete the test in each module. Each test consists of 4 multiple-choice questions, each of which is worth 1 point.

ABOUT

EXCELLENCE IN PEDIATRICS INSTITUTE

The Excellence in Pediatrics Institute (EIPI) is a not-for-profit association that provides continuing medical education to a global network of over 45,000 child healthcare professionals. EIPI aims to act as a hub for sharing the latest developments and advice with all stakeholders involved in caring for children and adolescents. By leveraging the collective expertise and research of leading global pediatric healthcare professionals, EIPI aims to facilitate an open exchange of scientific knowledge and clinical best practices. EIPI strives to build a global community of child healthcare professionals that nurtures and supports their continuing education requirements and ever-changing needs.


THE SPOT THE EARLY SIGNS PROGRAM

The program aims to fight under-diagnosed or late-diagnosed conditions for which treatments are available and where early detection and treatment could make a significant difference in the condition's development, the quality of life and the survival of patients. Following a Peer2Peer educational approach, the program aims to improve everyday practice and how child healthcare professionals advise and treat the children and families they support. Pediatricians and family doctors are likely to be the first healthcare professionals to observe symptoms, and it is important to help these front-line clinicians suspect, diagnose, and refer patients.


DISCLOSURE

This webinar is supported by Chiesi Farmaceutici S.p.A. This information is intended for healthcare professionals only.